Similar articles

• Interpretation of Mass Spectral Data for the Cisplatin 1,2 Intrastrand Guanine-Guanine Adduct.

  Wang P, Giese RW. Wang P, et al. Chem Res Toxicol. 2018 Nov 19;31(11):1106-1107. doi: 10.1021/acs.chemrestox.8b00134. Epub 2018 Oct 16. Chem Res Toxicol. 2018. PMID: 30280575 Free PMC article. No abstract available.
• Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.

  Harrington CF, Le Pla RC, Jones GD, Thomas AL, Farmer PB. Harrington CF, et al. Chem Res Toxicol. 2010 Aug 16;23(8):1313-21. doi: 10.1021/tx100023c. Chem Res Toxicol. 2010. PMID: 20666396
• Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin.

  Scheeff ED, Briggs JM, Howell SB. Scheeff ED, et al. Mol Pharmacol. 1999 Sep;56(3):633-43. Mol Pharmacol. 1999. PMID: 10462551
• Quantitative analysis of malondialdehyde-guanine adducts in genomic DNA samples by liquid chromatography/tandem mass spectrometry.

  Yates SA, Dempster NM, Murphy MF, Moore SA. Yates SA, et al. Rapid Commun Mass Spectrom. 2017 May 15;31(9):762-770. doi: 10.1002/rcm.7843. Rapid Commun Mass Spectrom. 2017. PMID: 28231608
• Preclinical perspectives on platinum resistance.

  Kelland LR. Kelland LR. Drugs. 2000;59 Suppl 4:1-8; discussion 37-8. doi: 10.2165/00003495-200059004-00001. Drugs. 2000. PMID: 10864225 Review.